Moreover, we unveiled COL5A2 as a novel biomarker with potential diagnostic value and predictive capacity for anti-TNF treatment responsiveness, elucidating its ties to immune cells and implicating it in CD pathophysiology. This evidence concerns the gene COL5A2 and Cowden disease.